Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis

被引:21
作者
Safikhani, Shima
Sundaram, Murali [2 ]
Bao, Yanjun [2 ]
Mulani, Parvez [2 ]
Revicki, Dennis A. [1 ]
机构
[1] United BioSource Corp, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA
[2] Abbott Labs, Global Hlth Econ & Outcomes Res, Abbott Pk, IL USA
关键词
content validity; DLQI; psoriasis; cognitive interviews; qualitative analysis; TO-SEVERE PSORIASIS; RANDOMIZED CONTROLLED-TRIAL; OF-LIFE; REPORTED OUTCOMES; ADALIMUMAB TREATMENT; DOUBLE-BLIND; CLINICAL-TRIAL; IMPACT; IMPROVEMENT; THERAPY;
D O I
10.3109/09546634.2011.631980
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The patient-reported Dermatology Life Quality Index (DLQI) measures the impact of dermatologic diseases on patients' lives. Objectives: To evaluate the content validity of the DLQI in patients with moderate to severe plaque psoriasis. Methods: In a two-part interview, participants were first asked open-ended questions about the impact of psoriasis-related complaints and symptoms on their lives and activities. The DLQI was then administered and cognitive debriefing interviews assessed participants' understanding of the instructions, items, and response scales, and relevance of the specific items to their experience with psoriasis. Results: Twenty-one patients were interviewed at two US sites. Mean age was 48.8 years, 67% were white, and 43% reported Hispanic/Latino ethnicity. The majority reported living with a partner or spouse (81%) and working full time or part time (57%). Patients' spontaneous responses to open-ended questions were consistent with DLQI concepts and generally did not provide additional concepts. Most participants reported that the instructions, item content, and response scales were clear and easy to understand and relevant. Conclusions: The content of the DLQI included all important and relevant concepts from the perspective of patients with moderate to severe plaque psoriasis. This study provides further support for the content validity of the DLQI in this population.
引用
收藏
页码:50 / 59
页数:10
相关论文
共 59 条
[1]  
[Anonymous], NAT PSOR FDN PSOR ST
[2]  
Badia X, 1999, BRIT J DERMATOL, V141, P698
[3]   Administration of DAB389IL-2 to patients with recalcitrant psoriasis:: A double-blind, phase II multicenter trial [J].
Bagel, J ;
Garland, WT ;
Breneman, D ;
Holick, M ;
Littlejohn, TW ;
Crosby, D ;
Faust, H ;
Fivenson, D ;
Nichols, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 38 (06) :938-944
[4]  
Creswell J. W., 2018, Qualitative inquiry research design: Choosing among five approaches, DOI DOI 10.1177/1524839915580941
[5]  
De Arruda LHF, 2001, BRIT J DERMATOL, V144, P33, DOI 10.1046/j.1365-2133.2001.00034.x
[6]   Quality of life in patients with psoriasis: A systematic literature review [J].
de Korte, J ;
Sprangers, MAG ;
Mombers, FMC ;
Bos, JD .
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2004, 9 (02) :140-147
[7]   Evaluation of item candidates - The PROMIS qualitative item review [J].
DeWalt, Darren A. ;
Rothrock, Nan ;
Yount, Susan ;
Stone, Arthur A. .
MEDICAL CARE, 2007, 45 (05) :S12-S21
[8]   Psoriasis has a major secondary impact on the lives of family members and partners [J].
不详 .
BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (06) :1245-1250
[9]   Effects of alefacept on health-related quality of life in patients with psoriasis - Results from a randomized, placebo-controlled phase II trial [J].
Ellis, CN ;
Mordin, MM ;
Adler, EY .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2003, 4 (02) :131-139
[10]   Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis [J].
Feldman, S. R. ;
Gottlieb, A. B. ;
Bala, M. ;
Wu, Y. ;
Eisenberg, D. ;
Guzzo, C. ;
Li, S. ;
Dooley, L. T. ;
Menter, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (03) :704-710